Article
Months after achieving unicorn status, Orca steers into the fast lane with an RMAT designation for
Rating:
0.0
Views:
152
Likes:
1
Library:
1
A few months after its last big catch — a $192 million Series D and rare unicorn status — Orca Bio has reeled in the FDA's regenerative medicine advanced therapy (RMAT) designation for its experimental cell therapy to treat blood stem cell transplant patients. Orca, one of this year's Endpoints
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value